University of Strathclyde stakes partnership in $74M U.K. manufacturing innovation center

Glasgow, Scotland
The University of Strathclyde is joining a partnership backing the new $74 million Medicines Manufacturing Innovation Center near Glasgow. (Getty Images)

Scotland’s University of Strathclyde is joining a partnership backing the new $74 million (£56 million) Medicines Manufacturing Innovation Center, which is touted as a first of its kind for the development of new pharmaceutical manufacturing techniques.

The center, which also is getting industry support, will focus on providing both large pharma and start-up companies with novel drug manufacturing processes that will help bring new medicines to market much faster, the university said. 

Located in Renfrewshire near the $86 million National Manufacturing Institute for Scotland on the outskirts of Glasgow, the center hopes to raise more than $106 million in R&D investments by 2028. The project is expected to employ 80 by 2023. 

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“Strathclyde has earned an international reputation for research and innovation that accelerates and enhances the manufacturing of medicines and pharmaceuticals,” Sir Jim McDonald, Strathclyde principal professor, said in a statement. “As strategic partners in MMIC, we will have an enhanced role in supporting industry to deliver urgently-needed medicines both swiftly and effectively.”

Industry supporters for the new center include AstraZeneca and GlaxoSmithKline. Last summer, GSK opened a $56.6 million vaccines plant in Montrose, Scotland, that manufactures sterile aluminum salts.

Suggested Articles

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.

Turkey is getting its first locally produced mAb via an Iranian biosimilars marker and the $100 million plant it built there.

Teva is recalling 10 more lots of losartan as blood pressure drugs tainted with suspected carcinogens continue to pop up in the U.S. supply chain.